2 Economic Costs of Diabetes in the U.S. in 2012 By care.diabetesjournals.org Published On :: 2013-04-01 American Diabetes AssociationApr 1, 2013; 36:1033-1046Scientific Statement Full Article
2 Moderate earthquake in Iran hits near Tehran; 2 dead By www.upi.com Published On :: Fri, 08 May 2020 07:48:58 -0400 At least two people died and more than a dozen were hurt Friday when a moderate earthquake struck in Iran's northern city of Damavand, near Tehran. Full Article
2 Northrop Grumman awarded $123.5M to integrate Navy LAIRCM system By www.upi.com Published On :: Fri, 01 May 2020 19:14:31 -0400 Northrop Grumman received a $123.5 million contract modification Friday to integrate the Department of Navy Large Aircraft Infrared Countermeasures system onto aircraft for the U.S. military and two allied governments. Full Article
2 Raytheon awarded $325M for repair of ATFLIR system for Navy Super Hornets By www.upi.com Published On :: Tue, 05 May 2020 19:29:57 -0400 Raytheon was awarded a $325 million contract for repair of the Advanced Targeting Forward Looking Infrared System in the F/A-18 Super Hornet aircraft Tuesday, according to the Pentagon. Full Article
2 Bell Boeing awarded $10.2M for V-22 Osprey repairs By www.upi.com Published On :: Tue, 05 May 2020 20:09:02 -0400 Bell Boeing received a $10.2 million contract modification Tuesday for repairs of the V-22 Osprey multirole combat aircraft for the Navy, the Pentagon announced. Full Article
2 3M inks $126M deal with DoD to increase N95 mask production in October By www.upi.com Published On :: Wed, 06 May 2020 18:14:28 -0400 3M has signed a $126 million deal with the Pentagon to increase its production of N95 masks to 26 million per month beginning in October 2020. Full Article
2 Boeing awarded $128.5M modification to GMD missile upgrade contract By www.upi.com Published On :: Thu, 07 May 2020 19:36:45 -0400 Boeing was awarded a $128.5 million modification to its Ground-based Midcourse Defense development and sustainment contract Thursday, according to the Pentagon. Full Article
2 Starting Aug. 1, DoD sites won't sell tobacco to people under 21 By www.upi.com Published On :: Fri, 08 May 2020 13:49:52 -0400 The Department of Defense announced this week that effective Aug. 1, retailers on U.S. military installations and bases will no longer sell tobacco products to anyone under the age of 21, including service members. Full Article
2 Professional Practice Committee: Standards of Medical Care in Diabetes--2019 By care.diabetesjournals.org Published On :: 2019-01-01 Jan 1, 2019; 42:S3-S3Professional Practice Committee Full Article
2 Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030 By care.diabetesjournals.org Published On :: 2018-05-01 Christian BommerMay 1, 2018; 41:963-970The Costs Of Diabetes Full Article
2 Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations By care.diabetesjournals.org Published On :: 2016-06-01 Francesco RubinoJun 1, 2016; 39:861-877Metabolic Surgery and the Changing Landscape for Diabetes Care Full Article
2 Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study By care.diabetesjournals.org Published On :: 2016-10-01 Khalid A. JadoonOct 1, 2016; 39:1777-1786Emerging Technologies and Therapeutics Full Article
2 PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes By care.diabetesjournals.org Published On :: 2019-09-01 Vanita R. ArodaSep 1, 2019; 42:1724-1732Emerging Therapies: Drugs and Regimens Full Article
2 Disclosures: Standards of Medical Care in Diabetes--2020 By care.diabetesjournals.org Published On :: 2020-01-01 Jan 1, 2020; 43:S205-S206Disclosures Full Article
2 SGLT2 Inhibitors and the Diabetic Kidney By care.diabetesjournals.org Published On :: 2016-08-01 Paola FiorettoAug 1, 2016; 39:S165-S171III. SGLT2 Therapy Full Article
2 Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors Expert Forum By care.diabetesjournals.org Published On :: 2018-01-01 William T. CefaluJan 1, 2018; 41:14-31Diabetes Care Expert Forum Full Article
2 Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial By care.diabetesjournals.org Published On :: 2020-05-01 W. Timothy GarveyMay 1, 2020; 43:1085-1093Emerging Therapies: Drugs and Regimens Full Article
2 Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial By care.diabetesjournals.org Published On :: 2019-12-01 Helena W. RodbardDec 1, 2019; 42:2272-2281Emerging Therapies: Drugs and Regimens Full Article
2 Guideline Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes By care.diabetesjournals.org Published On :: 2013-08-01 Itamar RazAug 1, 2013; 36:S139-S144Diabetes Pathophysiology Full Article
2 2017 National Standards for Diabetes Self-Management Education and Support By care.diabetesjournals.org Published On :: 2017-10-01 Joni BeckOct 1, 2017; 40:1409-1419National Standards Full Article
2 Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back: Recommendations of the Israel National Diabetes Council By care.diabetesjournals.org Published On :: 2016-08-01 Ofri MosenzonAug 1, 2016; 39:S146-S153II. Diabetes Treatment Options Full Article
2 Economic Costs of Diabetes in the U.S. in 2017 By care.diabetesjournals.org Published On :: 2018-05-01 American Diabetes AssociationMay 1, 2018; 41:917-928The Costs Of Diabetes Full Article
2 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) By care.diabetesjournals.org Published On :: 2020-02-01 John B. BuseFeb 1, 2020; 43:487-493Consensus Report Update Full Article
2 Professional Practice Committee: Standards of Medical Care in Diabetes--2020 By care.diabetesjournals.org Published On :: 2020-01-01 Jan 1, 2020; 43:S3-S3Professional Practice Committee Full Article
2 Association of Urine Haptoglobin With Risk of All-Cause and Cause-Specific Mortality in Individuals With Type 2 Diabetes: A Transethnic Collaborative Work By care.diabetesjournals.org Published On :: 2020-02-20T11:55:30-08:00 OBJECTIVE Haptoglobin is an acute-phase reactant with pleiotropic functions. We aimed to study whether urine haptoglobin may predict risk of mortality in people with type 2 diabetes. RESEARCH DESIGN AND METHODS We employed a transethnic approach with a cohort of Asian origin (Singapore) (N = 2,061) and a cohort of European origin (France) (N = 1,438) included in the study. We used survival analyses to study the association of urine haptoglobin with risk of all-cause and cause-specific mortality. RESULTS A total of 365 and 525 deaths were registered in the Singapore cohort (median follow-up 7.5 years [interquartile range 3.5–12.8]) and French SURDIAGENE cohort (median follow-up 6.8 years [interquartile range 4.3–10.5], respectively. Singapore participants with urine haptoglobin in quartiles 2 to 4 had higher risk for all-cause mortality compared with quartile 1 (unadjusted hazard ratio [HR] 1.47 [95% CI 1.02–2.11], 2.28 [1.62–3.21], and 4.64 [3.39–6.35], respectively). The association remained significant in quartile 4 after multiple adjustments (1.68 [1.15–2.45]). Similarly, participants in the French cohort with haptoglobin in quartile 4 had significantly higher hazards for all-cause mortality compared with quartile 1 (unadjusted HR 2.67 [2.09–3.42] and adjusted HR 1.49 [1.14–1.96]). In both cohorts, participants in quartile 4 had a higher risk of mortality attributable to cardiovascular disease and infection but not malignant tumor. CONCLUSIONS Urine haptoglobin predicts risk of mortality independent of traditional risk factors, suggesting that it may potentially be a novel biomarker for risk of mortality in patients with type 2 diabetes. Full Article
2 A Multinational, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy of Cyclical Topical Wound Oxygen (TWO2) Therapy in the Treatment of Chronic Diabetic Foot Ulcers: The TWO2 Study By care.diabetesjournals.org Published On :: 2020-02-20T11:55:30-08:00 OBJECTIVE Topical oxygen has been used for the treatment of chronic wounds for more than 50 years. Its effectiveness remains disputed due to the limited number of robust high-quality investigations. The aim of this study was to assess the efficacy of multimodality cyclical pressure Topical Wound Oxygen (TWO2) home care therapy in healing refractory diabetic foot ulcers (DFUs) that had failed to heal with standard of care (SOC) alone. RESEARCH DESIGN AND METHODS Patients with diabetes and chronic DFUs were randomized (double-blind) to either active TWO2 therapy or sham control therapy—both in addition to optimal SOC. The primary outcome was the percentage of ulcers in each group achieving 100% healing at 12 weeks. A group sequential design was used for the study with three predetermined analyses and hard stopping rules once 73, 146, and ultimately 220 patients completed the 12-week treatment phase. RESULTS At the first analysis point, the active TWO2 arm was found to be superior to the sham arm, with a closure rate of 41.7% compared with 13.5%. This difference in outcome produced an odds ratio (OR) of 4.57 (97.8% CI 1.19, 17.57), P = 0.010. After adjustment for University of Texas Classification (UTC) ulcer grade, the OR increased to 6.00 (97.8% CI 1.44, 24.93), P = 0.004. Cox proportional hazards modeling, also after adjustment for UTC grade, demonstrated >4.5 times the likelihood to heal DFUs over 12 weeks compared with the sham arm with a hazard ratio of 4.66 (97.8% CI 1.36, 15.98), P = 0.004. At 12 months postenrollment, 56% of active arm ulcers were closed compared with 27% of the sham arm ulcers (P = 0.013). CONCLUSIONS This sham-controlled, double-blind randomized controlled trial demonstrates that, at both 12 weeks and 12 months, adjunctive cyclical pressurized TWO2 therapy was superior in healing chronic DFUs compared with optimal SOC alone. Full Article
2 ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study By care.diabetesjournals.org Published On :: 2020-03-20T11:50:34-07:00 OBJECTIVE To determine whether ACE inhibitors reduce the risk of type 2 diabetes using a Mendelian randomization (MR) approach. RESEARCH DESIGN AND METHODS A two-sample MR analysis included 17 independent genetic variants associated with ACE serum concentration in 4,147 participants from the Outcome Reduction with Initial Glargine INtervention (ORIGIN) (clinical trial reg. no. NCT00069784) trial, and their effects on type 2 diabetes risk were estimated from 18 studies of the DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) consortium. A genetic risk score (GRS) underpinning lower ACE concentration was then tested for association with type 2 diabetes prevalence in 341,872 participants, including 16,320 with type 2 diabetes, from the UK Biobank. MR estimates were compared after standardization for blood pressure change, with the estimate obtained from a randomized controlled trial (RCT) meta-analysis of ACE inhibitors versus placebo (n = 31,200). RESULTS Genetically lower ACE concentrations were associated with a lower risk of type 2 diabetes (odds ratio [OR] per SD 0.92 [95% CI 0.89–0.95]; P = 1.79 x 10–7). This result was replicated in the UK Biobank (OR per SD 0.97 [0.96–0.99]; P = 8.73 x 10–4). After standardization, the ACE GRS was associated with a larger decrease in type 2 diabetes risk per 2.4-mmHg lower mean arterial pressure (MAP) compared with that obtained from an RCT meta-analysis (OR per 2.4-mmHg lower MAP 0.19 [0.07–0.51] vs. 0.76 [0.60–0.97], respectively; P = 0.007 for difference). CONCLUSIONS These results support the causal protective effect of ACE inhibitors on type 2 diabetes risk and may guide therapeutic decision making in clinical practice. Full Article
2 Time Course of Normalization of Functional {beta}-Cell Capacity in the Diabetes Remission Clinical Trial After Weight Loss in Type 2 Diabetes By care.diabetesjournals.org Published On :: 2020-03-20T11:50:34-07:00 OBJECTIVE To assess functional β-cell capacity in type 2 diabetes during 2 years of remission induced by dietary weight loss. RESEARCH DESIGN AND METHODS A Stepped Insulin Secretion Test with Arginine was used to quantify functional β-cell capacity by hyperglycemia and arginine stimulation. Thirty-nine of 57 participants initially achieved remission (HbA1c <6.5% [<48 mmol/mol] and fasting plasma glucose <7 mmol/L on no antidiabetic drug therapy) with a 16.4 ± 7.7 kg weight loss and were followed up with supportive advice on avoidance of weight regain. At 2 years, 20 participants remained in remission in the study. A nondiabetic control (NDC) group, matched for age, sex, and weight after weight loss with the intervention group, was studied once. RESULTS During remission, median (interquartile range) maximal rate of insulin secretion increased from 581 (480–811) pmol/min/m2 at baseline to 736 (542–998) pmol/min/m2 at 5 months, 942 (565–1,240) pmol/min/m2 at 12 months (P = 0.028 from baseline), and 936 (635–1,435) pmol/min/m2 at 24 months (P = 0.023 from baseline; n = 20 of 39 of those initially in remission). This was comparable to the NDC group (1,016 [857–1,507] pmol/min/m2) by 12 (P = 0.064) and 24 (P = 0.244) months. Median first-phase insulin response increased from baseline to 5 months (42 [4–67] to 107 [59–163] pmol/min/m2; P < 0.0001) and then remained stable at 12 and 24 months (110 [59–201] and 125 [65–166] pmol/min/m2, respectively; P < 0.0001 vs. baseline) but lower than that of the NDC group (250 [226–429] pmol/min/m2; P < 0.0001). CONCLUSIONS A gradual increase in assessed functional β-cell capacity occurred after weight loss, becoming similar to that of NDC group participants by 12 months. This result was unchanged at 2 years with continuing remission of type 2 diabetes. Full Article
2 Invertir en el Vecindario: Cambios en los Patrones de Migración Entre México y Estados Unidos y Oportunidades para una Cooperación Sostenible By www.migrationpolicy.org Published On :: Fri, 20 Sep 2019 11:31:12 -0400 Presentación del reporte que refleja el contenido de encuentros del grupo de estudio sobre la migración México-Estados Unidos convocado por El Colegio de México y el Migration Policy Institute (MPI). Full Article
2 A New Migration Policy for A New Era: A Conversation with Mexico's Interior Secretary Olga Sánchez Cordero By www.migrationpolicy.org Published On :: Thu, 28 Feb 2019 14:38:21 -0500 On her first official trip to Washington, DC, Secretary of the Interior Olga Sánchez Cordero offered a public address on Mexico’s new approach to migration policy at MPI. Her remarks and the event discussion were mostly conducted in Spanish, and this recording is of the simultaneous English interpretation. Full Article
2 Una nueva política migratoria para una nueva era: Una conversación con la Secretaria de Gobernación Olga Sánchez Cordero By www.migrationpolicy.org Published On :: Thu, 28 Feb 2019 18:28:45 -0500 Durante su primera visita oficial a Washington, DC, la Secretaria de Gobierno Olga Sánchez Cordero presento un discurso público sobre la nueva política migratoria de México en el Instituto de Políticas Migratorias. Full Article
2 Soluciones estratégicas para afrontar la crisis migratoria en Estados Unidos y México By www.migrationpolicy.org Published On :: Wed, 17 Jul 2019 17:27:19 -0400 Dado el incremento de los flujos migratorios provenientes de Centroamérica, el pasado mes de junio de 2019, los Estados Unidos y México acordaron tomar una serie de medidas para reducir los flujos irregulares. Sin embargo, será muy difícil mantener estos esfuerzos de corto plazo, debido a una debilidad institucional crónica y a estructuras de política pública poco planificadas en ambos países. Este comentario ofrece cinco recomendaciones a ambos países considerando soluciones de mediano y largo plazo para disuadir la migración irregular y, al mismo tiempo, garantizar que aquellos que busquen protección tengan un proceso justo. Full Article
2 Rutherford Test 2020_0226 By www.ada.org Published On :: Wed, 26 Feb 2020 14:56:59 -0600 Full Article
2 Dentists rank No. 2 in U.S. News & World Report’s Best Jobs report By www.ada.org Published On :: Tue, 14 Jan 2020 07:58:00 -0600 Dentists leaped up to No. 2 in U.S. News & World Report’s annual rankings of the 100 Best Jobs, the magazine revealed on its website Jan. 7. Full Article
2 Dr. Loree Bolin is ADA’s 2020 Humanitarian Award recipient By www.ada.org Published On :: Thu, 16 Jan 2020 10:10:00 -0600 Dr. Loree Bolin’s humanitarian work has drawn accolades from the dental community in her home state of Washington, and now Dr. Bolin is being recognized nationally by being named the recipient of the ADA’s 2020 Humanitarian Award, bestowed by the ADA Board of Trustees. Full Article
2 Alliance of the ADA offers education, entertainment at Conference 2020 By www.ada.org Published On :: Tue, 21 Jan 2020 10:14:00 -0600 From courses on burnout, vaping and more to golf and a low-country boil, the Alliance of the American Dental Association's upcoming Conference 2020 in Charleston, South Carolina, will offer a variety of educational and entertainment opportunities. Full Article
2 2019 marks big year for Washington office By www.ada.org Published On :: Thu, 23 Jan 2020 11:56:00 -0600 The Association’s Washington office covered a wide range of advocacy issues in 2019 — from vaping to student loan reform to making sure dentistry was exempt from the U.S. Mexico-Tourism Act. Full Article
2 Scholarship applicants sought for 2020 Institute for Teaching and Learning By www.ada.org Published On :: Tue, 28 Jan 2020 09:44:00 -0600 This year’s Institute for Teaching Learning program is scheduled for Aug. 23-26 in Atlanta. Now in its 14th year, with over 700 alumni, the program combines presentations, discussions, small group activities and peer-to-peer learnings to give participants new teaching skills. The onsite program is followed by a six-month distance learning experience that include online activities and interactive webinars. Full Article
2 Looking back: ADA annual meeting welcomes more than 200,000 attendees since 2010 By www.ada.org Published On :: Fri, 31 Jan 2020 13:05:00 -0600 The last decade brought 236,658 attendees to the American Dental Association's annual meeting. The ADA will continue to build on that momentum with the ADA FDC Annual Meeting from Oct. 15-18 in Orlando, Florida. Full Article
2 Former ADA President Robert M. Anderton dies at 82 By www.ada.org Published On :: Tue, 18 Feb 2020 08:56:00 -0600 Dr. Robert M. Anderton, ADA president from 2000-01 and ADA trustee from 1995-99, died Feb. 14. Full Article
2 Learning, social opportunities abound at ADA FDC 2020 By www.ada.org Published On :: Wed, 26 Feb 2020 14:14:00 -0600 Registration opens April 22 for the ADA FDC Annual Meeting, which will offer a variety of learning and social opportunities for dentists and their teams to enjoy. Full Article
2 Narwhal exhibit to start U.S. tour March 28 By www.ada.org Published On :: Thu, 27 Feb 2020 12:22:00 -0600 Dr. Martin Nweeia began researching narwhals in 2000. He came to the conclusion that the prevailing research available about the narwhal’s tooth — such as Charles Darwin’s belief that the narwhal’s tooth was a secondary sexual characteristic like an antler or a horn — was only part of the story. Full Article
2 Infection control webinar from ADA, OSAP available late March 20 By www.ada.org Published On :: Thu, 19 Mar 2020 11:20:00 -0500 On March 20, the ADA will release an on-demand webinar offering answers to frequently asked questions about infection control protocol and procedures related to COVID-19. Full Article
2 EPA releases expanded list of SARS-CoV-2 disinfectants By www.ada.org Published On :: Thu, 26 Mar 2020 15:27:00 -0500 Washington — The Environmental Protection Agency announced March 13 that it was adding nearly 200 additional products that have qualified for use against SARS-CoV-2, the novel coronavirus that causes the disease COVID-19. Full Article
2 Two March 27 webinars focus on surviving financial storm caused by pandemic By www.ada.org Published On :: Thu, 26 Mar 2020 15:52:00 -0500 The ADA is presenting two free webinars March 27, aiming to help dentists financially weather the economic downturn during the COVID-19 outbreak and illustrate how ADA advocacy has helped turn the tide. Full Article
2 CODA site visits rescheduled to 2021 due to COVID-19 By www.ada.org Published On :: Wed, 08 Apr 2020 09:20:00 -0500 The Commission on Dental Accreditation announced April 3 that it will reschedule all postponed and remaining site visits this year, including regular/reaccreditation and special focused site visits, to 2021 in response to the COVID-19 pandemic. Full Article
2 ADA seeks participants for 2020 SNODENT review By www.ada.org Published On :: Thu, 09 Apr 2020 11:54:00 -0500 The American Dental Association is seeking qualified individuals to join a canvass committee to consider approval of the 2020 revision of the Systemized Nomenclature of Dentistry. Full Article
2 ADA streams webinar April 27 on respiratory protection By www.ada.org Published On :: Thu, 23 Apr 2020 14:40:00 -0500 A recorded webinar will stream April 27 outlining the Association’s interim recommendation for personal protective equipment in dental settings as some states consider loosening social distancing mandates. Full Article
2 SBA will resume accepting Paycheck Protection Program applications April 27 By www.ada.org Published On :: Sun, 26 Apr 2020 08:29:00 -0500 The Small Business Administration will resume accepting Paycheck Protection Program loan applications at 10:30 a.m. EST on April 27 from “approved lenders on behalf of any eligible borrower,” the agency said. Full Article
2 ADASRI manuscript wins 2020 William J. Gies Award in clinical research By www.ada.org Published On :: Mon, 04 May 2020 13:19:00 -0500 A manuscript authored by the American Dental Association Science & Research Institute and Council on Scientific Affairs won the 2020 William J. Gies Award in clinical research from the American and International Associations for Dental Research. Full Article
